The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Interactions of Transforming Growth Factor-β and Angiotensin II in Renal Fibrosis
Open accessAbstract
Overproduction of transforming growth factor-β clearly underlies tissue fibrosis in numerous experimental and human diseases. Transforming growth factor-β’s powerful fibrogenic action results from simultaneous stimulation of matrix protein synthesis, inhibition of matrix degradation, and enhanced integrin expression that facilitates matrix assembly. In animals, overexpression of transforming growth factor-β by intravenous injection, transient gene transfer, or transgene insertion has shown that the kidney is highly susceptible to rapid fibrosis. The same seems true in human disease, where excessive transforming growth factor-β has been demonstrated in glomerulonephritis, diabetic nephropathy, and hypertensive glomerular injury. A possible explanation for the kidney’s particular susceptibility to fibrosis may be the recent discovery of biologically complex interactions between the renin-angiotensin system and transforming growth factor-β. Alterations in glomerular hemodynamics can activate both the renin-angiotensin system and transforming growth factor-β. Components of the renin-angiotensin system act to further stimulate production of transforming growth factor-β and plasminogen activator inhibitor leading to rapid matrix accumulation. In volume depletion, transforming growth factor-β is released from juxtaglomerular cells and may act synergistically with angiotensin II to accentuate vasoconstriction and acute renal failure. Interaction of the renin-angiotensin system and transforming growth factor-β has important clinical implications. The protective effect of inhibition of the renin-angiotensin system in experimental and human kidney diseases correlates closely with the suppression of transforming growth factor-β production. This suggests that transforming growth factor-β, in addition to blood pressure, should be a therapeutic target. Higher doses or different combinations of drugs that block the renin-angiotensin system or entirely new drug strategies may be needed to achieve a greater antifibrotic effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Transforming Growth Factor β in Tissue Fibrosis
Epstein, F. H., Border, W. A., & Noble, N. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311907 · Cited by 3,069
Self-citationKagami, S., Border, W. A., Miller, D. E., & Noble, N. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117251 · Cited by 1,076
Self-citationControl of glomerular hypertension limits glomerular injury in rats with reduced renal mass.
Anderson, S., Meyer, T. W., Rennke, H. G., & Brenner, B. M. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112013 · Cited by 932
Cell-Associated Plasminogen Activation: Regulation and Physiological Functions
Saksela, O., & Rifkin, D. B. (1988) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.04.110188.000521 · Cited by 818
Sanderson, N., Factor, V, Nagy, P., Kopp, J., Kondaiah, P., Wakefield, L., Roberts, A. B., Sporn, M. B., & Thorgeirsson, S. S. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2572 · Cited by 671
Gibbons, G. H., Pratt, R. E., & Dzau, V. J. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115881 · Cited by 645
Impaired wound healing in mice with a disrupted plasminogen gene
Rømer, J., Bugge, T. H., Fyke, C., Lund, L. R., Flick, M. J., Degen, J. L., & Danø, K. (1996) · Nature Medicine · doi:10.1038/nm0396-287 · Cited by 561
Eitzman, D. T., McCoy, R. D., Zheng, X., Fay, W. P., Shen, T., Ginsburg, D., & Simon, R. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118396 · Cited by 558
Vaughan, D. E., Lazos, S. A., & Tong, K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117809 · Cited by 530
Role of aldosterone in the remnant kidney model in the rat.
Greene, E. L., Kren, S., & Hostetter, T. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118867 · Cited by 479
Renal protective effect of enalapril in diabetic nephropathy.
Bjorck, S., Mulec, H., Johnsen, S. A., Norden, G., & Aurell, M. (1992) · BMJ · doi:10.1136/bmj.304.6823.339 · Cited by 432
Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease.
Kopp, J. B., Factor, V. M., Mozes, M., Nagy, P., Sanderson, N., Böttinger, E. P., Klotman, P. E., & Thorgeirsson, S. S. (1996) · PubMed · Cited by 422
Expression of transforming growth factor-β isoforms in human glomerular diseases
Yamamoto, T., Noble, N. A., Cohen, A. H., Nast, C. C., Hishida, A., Gold, L. I., & Border, W. A. (1996) · Kidney International · doi:10.1038/ki.1996.65 · Cited by 418
Self-citationBakris, G. L., Copley, J. B., Vicknair, N., Sadler, R., & Leurgans, S. (1996) · Kidney International · doi:10.1038/ki.1996.480 · Cited by 417
Effect of Captopril on Heavy Proteinuria in Azotemic Diabetics
Taguma, Y., Kitamoto, Y., Futaki, G., Ueda, H., Monma, H., Ishizaki, M., Takahashi, H., Sekino, H., & Sasaki, Y. (1985) · New England Journal of Medicine · doi:10.1056/nejm198512263132601 · Cited by 412
Bjorck, S., Nyberg, G., Mulec, H., Granerus, G., Herlitz, H., & Aurell, M. (1986) · BMJ · doi:10.1136/bmj.293.6545.471 · Cited by 405
TGF-β in kidney fibrosis: A target for gene therapy
Border, W. A., & Noble, N. A. (1997) · Kidney International · doi:10.1038/ki.1997.190 · Cited by 379
Self-citationWolf, G., Haberstroh, U., & Neilson, E. G. (1992) · PubMed Central · Cited by 330
Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy.
Hommel, E., Parving, H. H., Mathiesen, E., Edsberg, B., Damkjaer Nielsen, M., & Giese, J. (1986) · BMJ · doi:10.1136/bmj.293.6545.467 · Cited by 308
Falk, R. J., Scheinman, J., Phillips, G., Orringer, E., Johnson, A., & Jennette, J. C. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204023261402 · Cited by 300
The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice.
Esther, C. R., Marino, E. M., Howard, T. E., Machaud, A., Corvol, P., Capecchi, M. R., & Bernstein, K. E. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119419 · Cited by 272
Feener, E. P., Northrup, J. M., Aiello, L. P., & King, G. L. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117786 · Cited by 255
Nguyen, G., Delarue, F., Berrou, J., Rondeau, E., & Sraer, J.-D. (1996) · Kidney International · doi:10.1038/ki.1996.511 · Cited by 241
Effects of antihypertensive drugs on glomerular morphology
Yoshida, Y., Kawamura, T., Ikoma, M., Fogo, A., & Ichikawa, I. (1989) · Kidney International · doi:10.1038/ki.1989.239 · Cited by 224
Angiotensin II blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathy
Shihab, F. S., Bennett, W. M., Tanner, A. M., & Andoh, T. F. (1997) · Kidney International · doi:10.1038/ki.1997.380 · Cited by 209
Reversal of Vascular and Renal Crises of Scleroderma by Oral Angiotensin-Converting-Enzyme Blockade
Lopez-Ovejero, J. A., Saal, S. D., D'Angelo, W. A., Cheigh, J. S., Stenzel, K. H., & Laragh, J. H. (1979) · New England Journal of Medicine · doi:10.1056/nejm197906213002505 · Cited by 207
ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade
Baricos, W. H., Cortez, S. L., El-Dahr, S. S., & Schnaper, H. W. (1995) · Kidney International · doi:10.1038/ki.1995.150 · Cited by 202
Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney.
Lee, L. K., Meyer, T. W., Pollock, A. S., & Lovett, D. H. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118143 · Cited by 197
Oikawa, T., Freeman, M., Lo, W., Vaughan, D. E., & Fogo, A. (1997) · Kidney International · doi:10.1038/ki.1997.20 · Cited by 194
Impaired arterial neointima formation in mice with disruption of the plasminogen gene.
Carmeliet, P., Moons, L., Ploplis, V, Plow, E., & Collen, D. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119148 · Cited by 187
Glomerular matrix accumulation is linked to inhibition of the plasmin protease system
Tomooka, S., Border, W. A., Marshall, B. C., & Noble, N. A. (1992) · Kidney International · doi:10.1038/ki.1992.442 · Cited by 186
Self-citationVéniant, M., Ménard, J., Bruneval, P., Morley, S., Gonzales, M. F., & Mullins, J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119000 · Cited by 174
Cattran, D. C., Greenwood, C., & Ritchie, S. (1994) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80980-2 · Cited by 172
Kakinuma, Y., Kawamura, T., Bills, T., Yoshioka, T., Ichikawa, I., & Fogo, A. (1992) · Kidney International · doi:10.1038/ki.1992.259 · Cited by 159
The paradox of the renin-angiotensin system in chronic renal disease
Rosenberg, M. E., Smith, L. J., Correa‐Rotter, R., & Hostetter, T. H. (1994) · Kidney International · doi:10.1038/ki.1994.52 · Cited by 157
Angiotensin in progressive renal diseases
Matsusaka, T., Hymes, J. L., & Ichikawa, I. (1996) · Journal of the American Society of Nephrology · doi:10.1681/asn.v7102025 · Cited by 157
Shihab, F. S., Yamamoto, T., Nast, C. C., et al. (1995) · Journal of the American Society of Nephrology · doi:10.1681/asn.v62286 · Cited by 147
Captopril and renal survival in patients with human immunodeficiency virus nephropathy
Kimmel, P. L., Mishkin, G. J., & Umana, W. O. (1996) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(96)90302-9 · Cited by 136
Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy.
Burns, G. C., Paul, S. K., Tóth, I., & Sivak, S. L. (1997) · Journal of the American Society of Nephrology · doi:10.1681/asn.v871140 · Cited by 132
Pimentel, J. L., Sundell, C. L., Wang, S., Kopp, J. B., Montero, Á., & Martínez–Maldonado, M. (1995) · Kidney International · doi:10.1038/ki.1995.407 · Cited by 130
Ruiz‐Ortega, M., González, S., Serón, D., Condom, E., Bustos, C., Largo, R., González, E., Ortíz, A., & Egido, J. (1995) · Kidney International · doi:10.1038/ki.1995.476 · Cited by 122
Baba, T., Murabayashi, S., & Takebe, K. (1989) · Diabetologia · doi:10.1007/bf00265402 · Cited by 118
Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats.
Kim, S., Ohta, K., Hamaguchi, A., Omura, T., Yukimura, T., Miura, K., Inada, Y., Wada, T., Ishimura, Y., & Chatani, F. (1994) · Hypertension · doi:10.1161/01.hyp.24.2.195 · Cited by 117
Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells
Kagami, S., Kuhara, T., Okada, K., Kuroda, Y., Border, W. A., & Noble, N. A. (1997) · Kidney International · doi:10.1038/ki.1997.96 · Cited by 111
Self-citationMimran, A., Insua, A., Ribstein, J., Monnier, L., Bringer, J., & Mirouze, J. (1988) · Journal of Hypertension · doi:10.1097/00004872-198811000-00011 · Cited by 97
Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies.
Rondeau, É., Mougenot, B., Lacave, R., Péraldi, M., Kruithof, E. K. O., & Sraer, J. (1990) · PubMed · Cited by 80
Zoja, C., Donadelli, R., Corna, D., Testa, D., Facchinetti, D., Maffi, R., Luzzana, E., Colosio, V., Bertani, T., & Remuzzi, G. (1997) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(97)90038-x · Cited by 79
Lee, Y. A., Liang, C., Lee, M. A., & Lindpaintner, K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11035 · Cited by 70
Bauer, J. H., Reams, G. P., Hewett, J. E., Klachko, D. M., Lau, A., Messina, C. R., & Knaus, V. L. (1992) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)70256-1 · Cited by 69
Type beta transforming growth factor affects adrenocortical cell-differentiated functions.
Feige, J., Cochet, C., Rainey, W. E., et al. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)76453-9 · Cited by 67
Captopril Treatment of Hypertension and Renal Failure in Systemic Lupus erythematosus
Herlitz, H., Edenö, C., Mulec, H., et al. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000183318 · Cited by 57
Relationship between capillary and systemic venous PO2 during nonhypoxic and hypoxic ventilation
Stein, J. C., Ellis, C. G., & Ellsworth, M. L. (1993) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1993.265.2.h537 · Cited by 49
The importance of context in cytokine action
Sporn, M. B. (1997) · Kidney International · doi:10.1038/ki.1997.184 · Cited by 41
Cited by
Safian, R. D., & Textor, S. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102083440607 · Cited by 1,068
Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases
Kim, S., & Iwao, H. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01434-0 · Cited by 983
Vascular Remodeling in Hypertension: Roles of Apoptosis, Inflammation, and Fibrosis
Intengan, H. D., & Schiffrin, E. L. (2001) · Hypertension · doi:10.1161/hy09t1.096249 · Cited by 979
Touyz, R. M., & Schiffrin, E. L. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01471-6 · Cited by 934
Mechanisms of Tubulointerstitial Fibrosis
Zeisberg, M., & Neilson, E. G. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010080793 · Cited by 868
Metadata
- Authors
- Border, W. A., & Noble, N. A.
- Venue
- Hypertension
- Published
- 1998-01
- Volume
- 31
- Issue
- 1
- Pages
- 181-188
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2128520582
- Cited by
- 447
- References
- 54
- FWCI
- 23.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.